A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
NCT ID: NCT00240370
Last Updated: 2010-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1159 participants
INTERVENTIONAL
2003-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Muraglitazar
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c ≥7.0% and ≤10.0%,currently receiving a stable dose of metformin 1500 to 2550 mg/day for at least 6 weeks prior to screening were enrolled in this study.
* Fasting C-peptide ≥1.0 ng/mL
* BMI≤41 kg/m2 mean fasting serum trig. ≤600 g/dL
Exclusion Criteria
* history of diabetic ketoacidosis, hyperosmolar nonketotic coma, insulin therapy, inability to take muraglitazar, pioglitazone, or metformin according to investigator brochure or labeling
* History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history of, or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Birmingham, Alabama, United States
Local Institution
Columbiana, Alabama, United States
Local Institution
Mesa, Arizona, United States
Local Institution
Peoria, Arizona, United States
Local Institution
Carlisle, Arkansas, United States
Local Institution
Jonesboro, Arkansas, United States
Local Institution
Little Rock, Arkansas, United States
Local Institution
Pine Bluff, Arkansas, United States
Local Institution
Sherwood, Arkansas, United States
Local Institution
Anaheim, California, United States
Local Institution
Artesia, California, United States
Local Institution
Encino, California, United States
Local Institution
Encintas, California, United States
Local Institution
Fresno, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
Northridge, California, United States
Local Institution
Denver, Colorado, United States
Local Institution
Hamden, Connecticut, United States
Local Institution
Altamonte Springs, Florida, United States
Local Institution
Hollywood, Florida, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Miami, Florida, United States
Local Institution
New Port Richie, Florida, United States
Local Institution
Saint Cloud, Florida, United States
Local Institution
West Palm Beach, Florida, United States
Local Institution
Honolulu, Hawaii, United States
Local Institution
Evansville, Indiana, United States
Local Institution
Lafayette, Indiana, United States
Local Institution
New Orleans, Louisiana, United States
Local Institution
Shreveport, Louisiana, United States
Local Institution
Baltimore, Maryland, United States
Local Institution
Detroit, Michigan, United States
Local Institution
Gulfport, Mississippi, United States
Local Institution
St Louis, Missouri, United States
Local Institution
Omaha, Nebraska, United States
Local Institution
Endwell, New York, United States
Local Institution
Cary, North Carolina, United States
Local Institution
Charlotte, North Carolina, United States
Local Institution
Raleigh, North Carolina, United States
Local Institution
Rudd, North Carolina, United States
Local Institution
Statesville, North Carolina, United States
Local Institution
Wilmington, North Carolina, United States
Local Institution
Winston-Salem, North Carolina, United States
Local Institution
Bellbrook, Ohio, United States
Local Institution
Maumee, Ohio, United States
Local Institution
Thornville, Ohio, United States
Local Institution
Oklahoma City, Oklahoma, United States
Local Institution
Portland, Oregon, United States
Local Institution
Camp Hill, Pennsylvania, United States
Local Institution
Melrose Park, Pennsylvania, United States
Local Institution
Pittsburgh, Pennsylvania, United States
Local Institution
West Chester, Pennsylvania, United States
Local Institution
Youngwood, Pennsylvania, United States
Local Institution
East Providence, Rhode Island, United States
Local Institution
Charleston, South Carolina, United States
Local Institution
Clinton, South Carolina, United States
Local Institution
Memphis, Tennessee, United States
Local Institution
Austin, Texas, United States
Local Institution
Carrollton, Texas, United States
Local Institution
Corpus Christi, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
Houston, Texas, United States
Local Institution
Midland, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Salt Lake City, Utah, United States
Local Institution
Lebanon, Virginia, United States
Local Institution
Spokane, Washington, United States
Local Institution
Tacoma, Washington, United States
Local Institution
Bluefield, West Virginia, United States
Local Institution
Red Deer, Alberta, Canada
Local Institution
Vancouver, British Columbia, Canada
Local Institution
Sarnia, Ontario, Canada
Local Institution
Bonaventure, Quebec, Canada
Local Institution
Drummondville, Quebec, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Rimouski, Quebec, Canada
Local Institution
Aguascalientes, Aguascalientes, Mexico
Local Institution
Chihuahua City, Chihuahua, Mexico
Local Institution
Mexico, Durango, Mexico
Local Institution
Tijuana, Estado de Baja California, Mexico
Local Institution
Mexico City, Mexico City, Mexico
Local Institution
Cuernavaca, Morelos, Mexico
Local Institution
Aguas Buenas, , Puerto Rico
Local Institution
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV168-025
Identifier Type: -
Identifier Source: org_study_id